Guardian

NHS England to offer weight-loss drugs to 1.2m people to reduce risk of heart attacks and strokes

Daily Mail

Weight-loss jabs to be given to 1.2m heart patients on the NHS in major treatment shift

The Telegraph

NHS to give fat jabs to 1.2m patients to stop heart attacks

Independent

More than one million people to get ‘life-changing’ weight loss drugs to prevent heart attacks and strokes

NHS England

Over a million people could be offered Wegovy to cut heart attack and stroke risk on the NHS

Nice

Injection for more than a million people to help prevent heart attacks and strokes recommended

Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity

London Hormone Clinic

Weight-loss drugs, like Ozempic, arent for everyone  London Hormone Clinic

Weight-loss drugs aren't a magic bullet. Lifestyle changes are key to lasting health

Metaculus

Oral Semaglutide Approval by 2027

The NHS in England will offer semaglutide in the form of Novo Nordisk's Wegovy to around 1.2 million people in the country with cardiovascular disease to reduce their risk of heart attacks and strokes.

The NHS in England will offer semaglutide in the form of Novo Nordisk's Wegovy to around 1.2 million people in the country with cardiovascular disease to reduce their risk of heart attacks and strokes.

The development follows guidance published by the National Institute for Health and Care Excellence (NICE) approving the weekly injection of the drug for adults with a BMI of 27 or above who have previously had a heart attack, stroke or peripheral arterial disease.

The development follows guidance published by the National Institute for Health and Care Excellence (NICE) approving the weekly injection of the drug for adults with a BMI of 27 or above who have previously had a heart attack, stroke or peripheral arterial disease.

NICE made the recommendation after clinical data from the SELECT trial, which enrolled 17,604 people, found that semaglutide reduced the risk of a major cardiovascular event (MACE) — such as a heart attack, stroke or cardiovascular death — by 20% compared with a placebo.

NICE made the recommendation after clinical data from the SELECT trial, which enrolled 17,604 people, found that semaglutide reduced the risk of a major cardiovascular event (MACE) — such as a heart attack, stroke or cardiovascular death — by 20% compared with a placebo.

The study also discovered that the cardiovascular benefit of semglutide appeared early in patients, before significant weight loss occurred, which NICE claimed suggested there was an independent "mechanism of action" at work, directly on the heart and blood vessels.

The study also discovered that the cardiovascular benefit of semglutide appeared early in patients, before significant weight loss occurred, which NICE claimed suggested there was an independent "mechanism of action" at work, directly on the heart and blood vessels.

The NHS will prescribe the weight-loss drug as a treatment option alongside its standard care, which includes other medications and lifestyle changes, such as a healthier diet, greater physical activity, stopping smoking and reducing alcohol intake.

The NHS will prescribe the weight-loss drug as a treatment option alongside its standard care, which includes other medications and lifestyle changes, such as a healthier diet, greater physical activity, stopping smoking and reducing alcohol intake.

In a statement, Health Minister Sharon Hodgson claimed that extending the drug's use to people with cardiovascular disease would act as a "lifesaver," with the NHS expecting to begin rolling out the jabs within months.

In a statement, Health Minister Sharon Hodgson claimed that extending the drug's use to people with cardiovascular disease would act as a "lifesaver," with the NHS expecting to begin rolling out the jabs within months.

Guardian #4883

Daily Mail #5964

The Telegraph #

Independent #5829

NHS England #

Nice #

London Hormone Clinic #

NPR #

Metaculus #

The NHS in England is set to offer semaglutide, sold under the brand name Wegovy, to around 1.2 million people with cardiovascular disease to reduce their risk of heart attacks and strokes.

The NHS in England is set to offer semaglutide, sold under the brand name Wegovy, to around 1.2 million people with cardiovascular disease to reduce their risk of heart attacks and strokes.

The National Institute for Health and Care Excellence approved the weekly injection for adults with a BMI of 27 or above who have previously had a heart attack, stroke or peripheral arterial disease. The drug will be prescribed alongside statins, a reduced-calorie diet and increased physical activity.

The National Institute for Health and Care Excellence approved the weekly injection for adults with a BMI of 27 or above who have previously had a heart attack, stroke or peripheral arterial disease. The drug will be prescribed alongside statins, a reduced-calorie diet and increased physical activity.

Clinical trial data from the SELECT study, which enrolled 17,604 people, found that semaglutide reduced the risk of a major cardiovascular event — such as a heart attack, stroke or cardiovascular death — by 20% compared with a placebo.

Clinical trial data from the SELECT study, which enrolled 17,604 people, found that semaglutide reduced the risk of a major cardiovascular event — such as a heart attack, stroke or cardiovascular death — by 20% compared with a placebo.

Researchers found the cardiovascular benefit of semaglutide appeared early in the trial, before significant weight loss occurred, suggesting the drug acts directly on the heart and blood vessels rather than solely through weight reduction.

Researchers found the cardiovascular benefit of semaglutide appeared early in the trial, before significant weight loss occurred, suggesting the drug acts directly on the heart and blood vessels rather than solely through weight reduction.

Health Minister Sharon Hodgson said weight-loss drugs are "a game changer in tackling obesity" and that extending their use to people with cardiovascular disease "will be a life saver." The NHS rollout is expected to begin within months.

Health Minister Sharon Hodgson said weight-loss drugs are "a game changer in tackling obesity" and that extending their use to people with cardiovascular disease "will be a life saver." The NHS rollout is expected to begin within months.

Prof. Riyaz Patel of University College London welcomed the decision but raised concerns about NHS capacity and equitable access, warning the rollout "must not become another example where access depends on where you live."

Prof. Riyaz Patel of University College London welcomed the decision but raised concerns about NHS capacity and equitable access, warning the rollout "must not become another example where access depends on where you live."

Wegovy is a genuine breakthrough for the 1.2 million people in England living with cardiovascular disease — cutting the risk of heart attacks and strokes by 20% on top of existing treatments. The SELECT trial proved this benefit kicks in before significant weight loss even occurs, meaning the drug works directly on the heart. Expanding NHS access to semaglutide is smart, cost-effective prevention that saves lives.

Wegovy is a genuine breakthrough for the 1.2 million people in England living with cardiovascular disease — cutting the risk of heart attacks and strokes by 20% on top of existing treatments. The SELECT trial proved this benefit kicks in before significant weight loss even occurs, meaning the drug works directly on the heart. Expanding NHS access to semaglutide is smart, cost-effective prevention that saves lives.

Wegovy is no magic bullet — 85% of people who stop taking it regain the weight, and long-term safety data simply doesn't exist yet. Treating obesity with expensive weekly injections ignores the root causes driving the health crisis and risks sidelining the lifestyle changes that actually deliver lasting results. Lifestyle medicine cuts coronary artery disease risk by over 80% without the side effects or the staggering cost.

Wegovy is no magic bullet — 85% of people who stop taking it regain the weight, and long-term safety data simply doesn't exist yet. Treating obesity with expensive weekly injections ignores the root causes driving the health crisis and risks sidelining the lifestyle changes that actually deliver lasting results. Lifestyle medicine cuts coronary artery disease risk by over 80% without the side effects or the staggering cost.

NHS to Offer Wegovy to 1.2M Heart Disease Patients

United Kingdom

Health

Wegovy is a genuine breakthrough for the 1.2 million people in England living with cardiovascular disease, which will cut their risk of a heart attack and stroke by 20%, as the SELECT trial has already proved. As a result, expanding NHS access to semaglutide is a cost-effective decision that will save lives when used with existing treatment options.

Wegovy is a genuine breakthrough for the 1.2 million people in England living with cardiovascular disease, which will cut their risk of a heart attack and stroke by 20%, as the SELECT trial has already proved. As a result, expanding NHS access to semaglutide is a cost-effective decision that will save lives when used with existing treatment options.

While semaglutide has its uses, it is crucial to remember that drugs like Wegovy are not magic bullets and lack long-term supporting data. Treating health conditions through expensive weekly injections ignores the root causes driving these ailments and risks sidelining the importance of lifestyle changes that are proven to deliver lasting results.

While semaglutide has its uses, it is crucial to remember that drugs like Wegovy are not magic bullets and lack long-term supporting data. Treating health conditions through expensive weekly injections ignores the root causes driving these ailments and risks sidelining the importance of lifestyle changes that are proven to deliver lasting results.

There is an 85% chance that oral semaglutide will be approved for the treatment of obesity by the FDA or EMA by 2027, according to the Metaculus prediction community.

There is an 85% chance that oral semaglutide will be approved for the treatment of obesity by the FDA or EMA by 2027, according to the Metaculus prediction community.

NHS to Offer Wegovy to 1.2M Heart Patients

NHS to Offer Wegovy to 1.2M Heart Disease Patients

The Spin

Metaculus Prediction

Articles on this story

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters

NHS to Offer Wegovy to 1.2M Heart Patients

NHS to Offer Wegovy to 1.2M Heart Disease Patients

The Spin

Metaculus Prediction

Articles on this story

Sign Up for Our Free NewslettersSign Up for Our Free Newsletters

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters